Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Isis Pharmaceuticals Q4 Revenue More Than Doubles; Loss Widens Anyway

Antisense drug developer Isis Pharmaceuticals (NASDAQ: ISIS  ) released its fourth-quarter earnings results before the opening bell this morning, pointing to a sizable uptick in recognized revenue, but also seeing its losses widen significantly from the year-ago period.

For the quarter, Isis reported total revenue of $42.2 million compared to just $19.9 million in the year-ago quarter, a 113% improvement. Research and development revenue due to its numerous collaborative agreements, rose to $41.3 million compared to $17.9 million during this quarter last year. Isis also tacked on nearly $1 million in licensing and royalty revenue.

Net loss, however, widened from just $2.6 million, or $0.03 per share, in the fourth quarter last year, to $24.3 million, or $0.21 per share as reported this morning. There were two primary reasons for this wider loss. First, research and development expenses soared by 34% to $57.4 million as Isis' pipeline has expanded to include later-stage studies, and even more experimental therapies. Secondly, Isis recognized a gain of $18.4 million last year from an investment in Regulus Therapeutics that wasn't present this year.

Since Isis is currently unprofitable, its remaining cash and cash burn rate are important. Isis ended the quarter with $656.8 million in cash, cash equivalents, and short-term investments, which was up notably from the $374.4 million it reported at the end of fiscal 2012. Isis attributed this leap to the $225 million in cash received from its drug development partners in 2013, as well as the $236 million raised via a share offering.

Looking ahead, Isis is projecting a fiscal 2014 net operating loss in the low $50 million range, consistent with the $51.7 million it lost from operations in fiscal 2013, and anticipates ending the year with more than $575 million in cash, implying a cash burn rate of around $80 million.

From a clinical perspective, Isis plans to end 2014 with three drugs in phase 3 development and another 10 in phase 2 development. Isis' CFO, Elizabeth Hougen, also noted in the press release that Isis has earned more than $16 million via its partners year-to-date.


Read/Post Comments (0) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2859292, ~/Articles/ArticleHandler.aspx, 8/29/2015 7:40:41 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated 22 hours ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 4:00 PM
ISIS $51.54 Down -0.02 -0.04%
Isis Pharmaceutica… CAPS Rating: *****